Could plasma sphingolipids be diagnostic or prognostic biomarkers for Alzheimer’s disease?-Reference-Cited by-同舟云学术

Could plasma sphingolipids be diagnostic or prognostic biomarkers for Alzheimer’s disease?

Published:2012-10-01 Issue:5 Volume:7 Page:525-536
ISSN:1758-4299
Container-title:Clinical Lipidology
language:en
Short-container-title:Clinical Lipidology

Author:

Mielke Michelle M¹,Haughey Norman J²

Affiliation:

1. Division of Epidemiology, Department of Health Sciences Research, College of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA

2. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA

Publisher

Informa UK Limited

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism

Link

https://www.tandfonline.com/doi/pdf/10.2217/clp.12.59

Reference81 articles.

1. Alzheimer’s Disease International. World Alzheimer Report 2009 Executive Summary. London, UK (2009).

2. Pimplikar SW, Nixon RA, Robakis NK, Shen J, Tsai LH. Amyloid-independent mechanisms in Alzheimer’s disease pathogenesis. J. Neurosci. 30(45), 14946–14954 (2010).

3. Mielke MM, Lyketsos CG. Lipids and the pathogenesis of Alzheimer’s disease: is there a link? Int. Rev. Psychiatry 18(2), 173–186 (2006).

4. Lütjohann D, Meichsner S, Pettersson H. Lipids in Alzheimer’s disease and their potential for therapy. Clin. Lipidol. 7(1), 65–78 (2012).

5. Haughey NJ, Bandaru VV, Bae M, Mattson MP. Roles for dysfunctional sphingolipid metabolism in Alzheimer’s disease neuropathogenesis. Biochim. Biophys. Acta 1801(8), 878–886 (2010).

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma metabolites distinguish dementia with Lewy bodies from Alzheimer’s disease: a cross-sectional metabolomic analysis;Frontiers in Aging Neuroscience;2024-01-04

2. Lipids modulates Tau and amyloid-β proteins in Alzheimer’s disease;Advances in Protein Chemistry and Structural Biology;2024

3. Investigating associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease;Alzheimer's Research & Therapy;2023-02-22

4. Neuronal deletion of nSMase2 reduces the production of Aβ and directly protects neurons;Neurobiology of Disease;2023-02

5. Blood-Based Biomarkers for Alzheimer’s Disease Diagnosis and Progression: An Overview;Cells;2022-04-17